Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AZD5153

Small molecule · Inhibitor of BRD4

Phase 2/3 Most advanced trial

1 Registered trials

What is AZD5153?

AZD5153 is an orally bioavailable bivalent inhibitor of bromodomain-containing protein 4 (BRD4). It selectively binds to acetylated lysine recognition motifs in BRD4's bromodomains, preventing BRD4 binding to acetylated histones and disrupting chromatin remodeling. This dysregulates growth-promoting genes, induces apoptosis, and inhibits proliferation in BRD4-overexpressing tumor cells. It is studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: BRD4
Mechanism: Inhibitor of BRD4
Pathways: chromatin remodeling, gene expression regulation, apoptosis
Therapy area: Hematology, Oncology
In trials of: SNDX
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: C7C7U6YEAO

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03013998	Phase 2/3	Previously Untreated Relapsed Refractory Acute Myeloid Leukemia	Recruiting	SNDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Other drugs acting on BRD4

NUV-868 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z